Indaptus Therapeutics Showcases Phase 1 Trial Data
Indaptus Therapeutics, Inc. (NASDAQ: INDP), a clinical-stage biotechnology company focused on innovative treatments for cancer and viral infections, recently presented interim findings from its Phase 1 clinical trial of Decoy20 during a prominent conference. The Society for Immunotherapy of Cancer (SITC) held its annual meeting, where the company unveiled encouraging safety, pharmacokinetics, and biomarker data.
Overview of the Clinical Trial
The findings were derived from two cohorts consisting of 13 patients who received single administrations of Decoy20, plus a cohort of 6 patients who received weekly doses during the trial. One key observation was that the intravenous administration of Decoy20 primarily resulted in mild to moderate side effects that faded shortly after treatment. Such results enhance the confidence in the safety profile of this promising therapeutic option.
Promising Patient Outcomes
Among the participants, a notable case was reported concerning a patient suffering from squamous cell carcinoma of the head and neck, who displayed high levels of PD-L1—a protein linked to tumor response under certain immunotherapies. This patient experienced “stable disease,” indicating that their cancer did not progress at the point of the initial imaging scan. This outcome suggests the potential of Decoy20 to maintain disease stability in challenging cancer cases.
Statements from Company Leadership
Dr. Roger Waltzman, Chief Medical Officer, expressed optimism regarding the findings: “We are encouraged by the safety profile of Decoy20 when administered weekly. We observe a robust innate and adaptive immune response. Based on our pre-clinical data, we anticipate that Decoy20, combined with a PD-1 inhibitor, will synergize effectively to control tumors.”
Expanding Patient Enrollment
The excitement doesn’t stop there; CEO Jeffrey Meckler shared insights about the ongoing developments, stating, “We’re thrilled to present our latest clinical data, which further validates our hypotheses in this Phase 1 trial. Our trial is now extending enrollment to include patients with six different tumor types for weekly dosing. Additionally, a collaboration with BeiGene to launch a new cohort combining Decoy20 with their PD-1 inhibitor, tislelizumab, is underway.” With each stride, Indaptus Therapeutics is unveiling the true potential of its Decoy platform.
About Indaptus Therapeutics
Indaptus Therapeutics roots can be traced back over a century of significant advancements in immunotherapy. The company’s innovative hypothesis centers on the activation of both innate and adaptive immune cells through a multi-faceted delivery of immune system-activating signals, which can be given safely via intravenous methods. The Decoy platform is distinct, employing a proprietary technology consisting of single strains of attenuated and non-pathogenic Gram-negative bacteria, designed to stimulate TLR, NLR, and STING pathways.
Clinical Applications and Research Findings
The Decoy product candidates demonstrate reduced intravenous toxicity while effectively activating a broad spectrum of immune responses. In rigorous pre-clinical investigations, these candidates have shown promising effects against various cancers, including metastatic pancreatic cancer and colorectal carcinoma, as well as successfully eliminating established antigen-expressing breast carcinoma in models that simulate human tumors. Such results sparking innate and adaptive memory in patients could reshape future cancer therapies.
Additionally, Decoy candidates have shown promising activity against chronic infections like hepatitis B and HIV in pre-clinical models. This highlights Indaptus' commitment to addressing not only cancer but also other viral challenges affecting human health.
Frequently Asked Questions
What is the main focus of Indaptus Therapeutics?
Indaptus Therapeutics is dedicated to developing innovative treatments for cancer and viral infections through unique immunotherapy approaches.
What is Decoy20?
Decoy20 is the lead product candidate from Indaptus Therapeutics, currently undergoing clinical trials to assess its safety and efficacy against various tumors.
What were the findings from the recent clinical trial?
The recent findings indicated that Decoy20 had a favorable safety profile with mostly mild side effects and promising responses in patients suffering from specific cancer types.
How does Decoy20 work?
Decoy20 works by activating immune responses through a novel approach, enhancing both innate and adaptive immunity to target tumor cells effectively.
What future plans does Indaptus have for Decoy20?
Indaptus is currently enrolling more patients for further evaluations and is exploring combinations of Decoy20 with PD-1 inhibitors to enhance treatment effectiveness.
